



- (51) **International Patent Classification:**
A61K 9/48 (2006.01) *A61K 31/506* (2006.01)
- (21) **International Application Number:**
PCT/IB2024/056936
- (22) **International Filing Date:**
17 July 2024 (17.07.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/514,042 17 July 2023 (17.07.2023) US
- (71) **Applicant: GRAVITON BIOSCIENCE BV** [NL/NL];
Herengracht 540, 1017 CG Amsterdam (NL).
- (72) **Inventors: WAKSAL, Samuel D.**; c/o Graviton Bioscience, 125 West End Ave, Suite 301, New York, New York 10023 (US). **WU, Rui**; c/o Graviton Bioscience, 125 West End Ave, Suite 301, New York, New York 10023 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

- (54) **Title:** FORMULATIONS OF ROCK2 INHIBITORS FOR CNS DISORDERS

FIG. 1

Mean pharmacokinetic profiles of lipid solid dispersion versus aqueous nanosuspension in male and female beagles (n=6)



- (57) **Abstract:** The disclosure provides methods for the treatment of cerebral cavernous malformation and Devic's disease with ROCK2 inhibitors. The disclosure also provides pharmaceutical formulations for the oral administration of ROCK2 inhibitors for use in the treatment of cerebral cavernous malformation and Devic's disease.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE